Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy

Archive ouverte

Vaflard, Pauline | Paoletti, Xavier | Servois, Vincent | Tresca, Patricia | Pons-Tostivint, E. | Sablin, Marie Paule | Ricci, Francesco | Loirat, Delphine | Hescot, Ségolène | Torossian, Nouritza | Bello Roufai, Diana | Kamal, Maud | Borcoman, Édith | Le Tourneau, Christophe

Edité par CCSD ; Springer Verlag -

International audience. Background: Immune checkpoint inhibitors have been demonstrated to improve overall survival. Atypical patterns of response have been reported, including dissociated response (DR). We evaluated the prevalence of DR. Patients and methods: Patients had to have a baseline computed tomography (CT) scan and at least one follow-up CT scan and two target lesions (TLs). Three types of DR were evaluated using RECIST1.1: DR1, defined as at least one progressive and one responding TL; DR2, defined as at least one progressive and one stable TL; and DR3, defined as at least one stable and one responding TL. Results: A total of 1244 measurements of 272 TLs were performed in 100 patients. Forty-nine out of the 272 TLs (18%) had received old or recent radiotherapy, and 42 (15%) had been biopsied. An objective response was observed in 22 patients (22%) and on 52 TLs (19%). DR1 were observed in 8% of patients. At the tumor measurement level, the response rate was lower in the case of prior radiotherapy (29% vs 34%, p = 0.01) and higher in the case of prior biopsy (40% vs 32%, p = 0.02). Conclusions: A DR was observed in 8% of patients. Response rate was lower in the case of prior radiotherapy and higher in the case of prior biopsy.

Suggestions

Du même auteur

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

Archive ouverte | Le Tourneau, Christophe | CCSD

International audience. Background: Molecularly targeted agents have been reported to have anti-tumour activity for patients whose tumours harbour the matching molecular alteration. These results have led to increas...

Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases

Archive ouverte | de Moura, Alexandre | CCSD

International audience. Background: Sacituzumab govitecan (SG) has been approved by FDA in April 2021 for pre-treated metastatic triple-negative breast cancer (mTNBC), following the ASCENT trial results. Methods: We...

COVID-19 in breast cancer patients: A cohort at the Institut Curie hospitals in the Paris area

Archive ouverte | Vuagnat, Perrine | CCSD

Auteurs : Institut Curie Breast Cancer and COVID Group. International audience. Background: Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics...

Chargement des enrichissements...